Review Article
Benign Prostatic Hyperplasia: A New Metabolic Disease of the Aging Male and Its Correlation with Sexual Dysfunctions
Table 2
Characteristics of the studies included in the meta-analysis.
| Overall population | Study | Age (years) | Duration (weeks) | Drugs | Dosage (mg) | Placebo number of pts | PDE5 number of pts |
| McVary et al., 2007 [113] | 60 | 12 | Sildenafil | 50 (2 weeks); 100 | 155 | 168 | McVary et al., 2007 [114]* | 61.5 | 12 | Tadalafil | 5 (6 weeks); 20 | 126 | 125 | Stief et al., 2008 [115] | 55.9 | 8 | Vardenafil | 10 | 110 | 105 | Roehrborn et al, 2008 [116]* | 62.0 | 12 | Tadalafil | 2.5; 5; 10; 20 | 185 | 701 | Porst et al., 2009 [117]* | 61.9 | 12 | Tadalafil | 2.5; 5; 10; 20 | 105 | 386 | Tamimi et al., 2010 [118]* | 60.9 | 12 | UK-369003 | 10; 25; 50, 100 | 37 | 246 | Porst et al., 2011 [119] | 64.8 | 12 | Tadalafil | 5 | 152 | 148 | Egerdie et al., 2012 [120]* | 62.5 | 12 | Tadalafil | 2.5; 5 | 200 | 406 | Oelke et al., 2012 [121] | 63.6 | 12 | Tadalafil | 5 | 172 | 171 | Brock et al., 2013 [122] | 63.3 | 12 | Tadalafil | 5 | 545 | 544 | Dmochwski et al., 2013 [123] | 58.6 | 12 | Tadalafil | 20 | 101 | 99 | Yokoyama et al., 2013 [124]* | 63.2 | 12 | Tadalafil | 2.5; 5 | 154 | 306 |
|
|
The effect derived from a ponderated mean at end point on International Prostate Symptom Score and maximum urinary flow rate were analyzed.
|